Primary tabs

The first cases of Ebola virus disease (EVD) were registered in Africa’s Sudan and Congo, and since then it has spread by contamination and human-to-human transmission to several parts of West Africa and surrounding regions.

Hailing from the Filoviridae family, the disease is incurable and, most often, fatal.



In an attempt to stop the virus in its tracks, scientists at the University of Copenhagen and Phillips Universität Marburg in Germany have successfully inhibited the Ebola virus in cell cultures by manipulating its host factor enzyme, PP2A-B56. This study has been published in the Molecular Cell journal.

Mechanism of Action of the Virus

On entering the body, the pathogen first affects the patient’s immune system, specifically the T lymphocytes on the dendritic cells, which are usually responsible for creating an immune response.

With the T cells failing to produce antibodies, the antigen can then start replicating at a rapid rate.

On a deeper level, the Ebola virus requires the host enzyme, PP2A-B56, which is present in all human cells, to replicate and produce more copies. On takeover, the virus promotes its own transcription instead of PP2A-B56 regulating the host’s metabolic processes.

After the virus breaks through this defense barrier, it affects tissues in the liver, abdomen and adrenal glands by killing cells that produce the clotting proteins, causing oxygen starvation and such. Ultimately, it is the drop-in blood pressure and multiple organ failure that is fatal to patients.

Ebola virus. (CC BY 2.0)

Inhibition of Ebola & Its Applications

The scientists decided to inhibit the activities of PP2A-B56 by using specific peptides to bind to the enzyme instead. This, in cell cultures, impeded the Ebola virus’ ability to transcribe and proliferate. Results from the study showed a 10x reduced EVD infection within 24 hours of the treatment.

Jack Nilsson of the Novo Nordisk Foundation Center for Protein Research said: “When the Ebola virus enters the human cell, its only purpose is to copy itself, fast. But by inhibiting a specific enzyme we rob the Ebola virus of its ability to copy itself. And that may potentially prevent an Ebola infection from spreading.”

For therapeutic options in the future, the team is working on developing molecules — as drugs — that when administered could play the role of the specific inhibitors in people living with the infection. Although a promising endeavor, there is yet a great deal of research to be conducted in this area, and also questions to be answered - Will this work on humans? Will this be viable for different strains of the virus? What is this method’s feasibility on other diseases that cause Ebola-like symptoms?

Co-author of the study, Prof. Nilsson, was confident that this general approach could be used to eliminate most viral strains of Ebola owing to their similar mechanisms of causing infection.

Top image: Scanning electron micrograph of Ebola virus budding from the surface of a Vero cell (African green monkey kidney epithelial cell line. Credit: NIAID. (CC BY 2.0)


Servick, K. (2014), Science,, (accessed 26 Jan 2018)

University of Copenhagen (2017), Science Daily,, (accessed 26 Jan 2018)

Kruse, T. et al. (2018), ‘The Ebola Virus Nucleoprotein Recruits the Host PP2A-B56 Phosphatase to Activate Transcriptional Support Activity of VP30’, Molecular Cell, 69 (1), Pp 136–145

Schuster, R. (2017), Haaretz,, (accessed 28 Jan 2018)

World Health Organization (2017),, (accessed 26 Jan 2018)

Meghna's picture

Meghna Rao, MSc

A postgraduate in Bioscience with work experience in research and communications in the fields of science, health and medicine. Her specializations include writing and developing scientific material for websites, blogs, and other print and digital media, content curation and management, and medical proofreading and editing. She also has a fair knowledge in marketing communications and science journalism. Also, Meghna is passionate about yoga, working with non-profits and travel blogging. Read More

No comment

Leave a Response